Dr. Adam Morgenthau: Mount Sinai Launches Clinical Trial to Treat Chronic Pulmonary Sarcoidosis
Patients are currently being enrolled in the first clinical trial to investigate the efficacy of immunological therapy for chronic pulmonary sarcoidosis. The trial is being conducted by researchers at the Icahn School of Medicine at Mount Sinai. "The current standard treatment for chronic pulmonary sarcoidosis is corticosteroids," said Adam Morgenthau, MD, principal investigator of the study and Director of the Sarcoidosis Clinic and the Alvin S. Teirstein Sarcoidosis Support Group at Mount Sinai. "Many patients don't respond to these drugs and those who do often develop long-term complications. We are hopeful this study will lead to new treatments to improve lung function and quality of life." Learn more
Mount Sinai Launches Institute for Airway Sciences
Jan 12, 2022 View All Press Releases
Clinical Trial Will Evaluate Saracatinib in Idiopathic Pulmonary Fibrosis
Jan 13, 2020 View All Press Releases